Therefore, people who use insulin or other glucose-lowering medicines may need closer monitoring
ORIGIN Trial Investigators, Gerstein HC, Bosch J et al (2012) Basal insulin and cardiovascular and other outcomes in dysglycemia
As chronic kidney disease overlaps with diabetes, obesity, and cardiovascular disease, this reinforces the need for integrated, cross-system treatment strategies
When managing your progress during GLP-1 treatment, dont just focus on the number on the scale
Our executive producer is Laura Beatty
This modification enables the molecule to bind and activate both GLP-1 and GIP receptors, thereby eliciting combined biochemical effects.61 Tirzepatide is a 39-amino acid linear synthetic peptide conjugated to a C20 fatty acid moiety